Markus Peterseim

Managing Director
Head of A&M Healthcare and Life Sciences Group in Germany
Over 25 years of experience in strategy, performance improvement consulting and interim management for healthcare sector
Fluent in German and English
Frankfurt
@alvarezmarsal
LinkedIn
Copied!
Markus Peterseim is a Managing Director with Alvarez & Marsal in Frankfurt, leading the Healthcare and Life Sciences group in Germany. He is deeply involved in serving the private equity sector.

He brings over 25 years of experience in strategy development and execution and performance improvement consulting as well as interim management in the healthcare industry. Mr. Peterseim has worked with clients in Europe, CEE/CIS and the Americas on a broad range of healthcare products and services, including pharma, CROs, CDMOs, wholesale, pharmacies and retail, medtech, HC providers and payers. He also served the chemical industry on performance improvement projects.

Recently, Mr. Peterseim completed numerous commercial due diligences for PE investors as well as strategy projects. Amongst others, he analyzed hospitals, a hospital procurement provider, a locum tenens platform, specialist physician networks, pharmaceutical as well as medtech companies. He led a range of value creation blueprints in major industrial carve-out situations and large-scale secondary buyouts, delivering comprehensive views on strategic and operational value drivers.

During his career, Mr. Peterseim served three years as interim CEO of ASTA Medica/Viatris – the former pharma division of Degussa. He was responsible for developing the strategic blueprint to sell the business. He developed a separation plan of the group and took over the CEO role for the largest division (c. € 500m in global sales). He drove the turnaround, all major performance improvement initiatives and sold the business to a PE fund.

As Partner of BCG he was responsible for the German payers and providers as well as private equity  in healthcare. He led large-scale payer programs on financial strategy and cost management and  assisted PE clients in due diligence and value creation. Prior to joining A&M, Mr. Peterseim was a PwC Deals Strategy Partner delivering diligence support for PE and corporates.

Mr. Peterseim earned a scl doctorate in chemistry from the University of Dortmund. He served as post-doc DFG fellow at Texas A&M University before starting his career in management consulting. He is also a speaker at private equity  conferences and has authored various articles on healthcare topics. A German national, Mr. Peterseim is proficient in German and English.

Insights By This Professional

Wie die richtige ERP-Implementierung im Pharmasektor nicht nur über den Erfolg eines Unternehmens entscheidet, sondern auch von Patienten wahrgenommen wird
Our whitepaper delves into the essential strategies for overcoming these hurdles and addressing challenges from data inconsistencies to compliance risks. It emphasizes the importance of realistic planning, use of the right system integrators, regular compliance audits, and strategic resource allocation to mitigate these risks.
Last year saw pharma M&A settle down into a slower pace as a result of macroeconomic uncertainty.
Should a company go private? There is no single answer to this question, it really depends on the specific situation of the company.
Latest insights The latest insights from Markus Peterseim's team
Thought Leadership
AI agents are making headlines in 2025. Learn how Corporate Performance Improvement experts are cutting through the hype to reveal what’s truly possible and what business leaders need to know before investing.
Contact me
FOLLOW & CONNECT WITH A&M